AHA Coding Clinic® for HCPCS - 2018 Issue 1; For Your Information
New HCPCS codes for the reporting of biosimilar products
Effective April 1, 2018, three new HCPCS codes will be available for the reporting of biosimilar products. Currently biosimilar products are reported with HCPCS code Q5102, Injection, infliximab, biosimilar, 10 mg, which will be discontinued on March 31, 2018. HCPCS code Q5102 will be replaced with HCPCS code Q5103 and Q5104, effective April 1 2018. Also, beginning April 1 2018, modifiers that describe the manufacturer of a biosimilar product (ie, ZA, ZB, and ZC) will no longer be required for Medicare reporting of HCPCS codes for biosimilar products. The new HCPCS codes and their code descriptors are listed in...
To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.